Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Chronic Pancreatitis II: Pathophysiology01:21

Chronic Pancreatitis II: Pathophysiology

Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...
Chronic Pancreatitis I: Introduction01:25

Chronic Pancreatitis I: Introduction

Chronic pancreatitis is a long-standing, relapsing inflammation of the pancreas, characterized by irreversible damage to the gland. It results in progressive destruction of the pancreatic parenchyma, fibrosis, and eventual loss of both exocrine and endocrine function. The disease may evolve gradually after multiple episodes of acute pancreatitis or develop independently.EtiologyChronic pancreatitis can arise from a variety of causes:Alcohol use is the leading cause, accounting for 70–80% of...
Chronic Pancreatitis I: Introduction01:24

Chronic Pancreatitis I: Introduction

The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Nationwide Assessment of Anticholestatic Therapy Uptake in Patients With Primary Biliary Cholangitis: Opportunities for Optimisation.

Alimentary pharmacology & therapeutics·2026
Same author

Fracture risk under selective and non-selective PPAR agonists in primary biliary cholangitis.

Hepatology communications·2026
Same author

Reply to 'The ethics of unlicensed therapy use in primary biliary cholangitis: a counter view'.

Nature reviews. Gastroenterology & hepatology·2026
Same author

Children's experience of screening and evaluation for MASLD in overweight and obesity.

Obesity research & clinical practice·2025
Same author

Effectiveness and tolerability of bezafibrate in primary biliary cholangitis - a nationwide real-world study.

The American journal of gastroenterology·2025
Same author

PD-L1 and the risk of bacterial infection in patients with chronic liver diseases: An international multicohort study.

JHEP reports : innovation in hepatology·2025
Same journal

The interaction between inflammation and estrogen in adenomyosis : from molecular mechanisms to therapeutic strategies.

Seminars in immunopathology·2026
Same journal

The complex of gut microbial metabolites and sex hormones in Alzheimer's disease.

Seminars in immunopathology·2026
Same journal

Endometrial pathophysiology and pregnancy: from mechanism to intervention.

Seminars in immunopathology·2026
Same journal

Advances in understanding the dual roles of testicular immune responses: From immune privilege to inflammation.

Seminars in immunopathology·2026
Same journal

Climate change-associated heat extremes and immune dysregulation: emerging links with autoimmunity, allergy, and infectious diseases.

Seminars in immunopathology·2026
Same journal

The cancer-microbiome axis: Mechanisms and emerging therapeutic strategies.

Seminars in immunopathology·2026
See all related articles

Related Experiment Videos

Primary biliary cirrhosis.

Simon Hohenester1, Ronald P J Oude-Elferink, Ulrich Beuers

  • 1Department of Gastroenterology & Hepatology/Liver Center, Academic Medical Center, G4-213, University of Amsterdam, P.O. Box 22700, 1100 DE, Amsterdam, The Netherlands.

Seminars in Immunopathology
|July 16, 2009
PubMed
Summary
This summary is machine-generated.

Primary biliary cirrhosis (PBC) is a chronic liver disease primarily affecting women. Ursodeoxycholic acid (UDCA) is the main treatment, offering normal life expectancy for many, but some require further therapy.

Related Experiment Videos

Area of Science:

  • Hepatology
  • Immunology
  • Gastroenterology

Background:

  • Primary biliary cirrhosis (PBC) is an immune-mediated chronic cholestatic liver disease.
  • It predominantly affects women and can lead to fibrosis, cirrhosis, and liver transplantation.
  • Diagnosis relies on cholestasis markers and antimitochondrial antibodies.

Purpose of the Study:

  • To review current knowledge on the clinical, diagnostic, pathogenetic, and therapeutic aspects of PBC.
  • To summarize the role and mechanisms of ursodeoxycholic acid (UDCA) in PBC treatment.
  • To highlight the unmet needs in PBC management for non-responders.

Main Methods:

  • Literature review of clinical, diagnostic, pathogenetic, and therapeutic aspects of PBC.
  • Analysis of diagnostic criteria including serum markers and histology.
  • Evaluation of ursodeoxycholic acid (UDCA) efficacy and mechanisms of action.

Main Results:

  • UDCA, at 13-15 mg/kg/day, normalizes life expectancy for two-thirds of PBC patients.
  • Potential UDCA mechanisms include enhanced secretion, bile detoxification, and antiapoptotic effects.
  • One-third of patients show inadequate response to UDCA, necessitating alternative treatments or transplantation.

Conclusions:

  • PBC is a complex autoimmune liver disease with evolving understanding of its pathogenesis.
  • UDCA is effective for a majority of patients, but therapeutic options for non-responders remain crucial.
  • Further research into PBC pathogenesis and treatment is needed for improved patient outcomes.